Changes in erythropoiesis‐stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan
Therapeutic Apheresis and Dialysis · 2023-08 · 27 (4) · 735-741
DOI: 10.1111/1744-9987.13981 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 22.03.2023. Verfasst von Yukio Maruyama und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Internal Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Hematinics, Peritoneal Dialysis, Kidney Failure, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: the Kidney Foundation, Japan.
Abstract (Originalsprache)
Introduction
Inadequate dialysis and fluid overload are corrected after starting combined therapy with peritoneal dialysis (PD) and hemodialysis (HD). However, the effects on anemia management has not been elucidated.
Methods
We conducted a prospective, multicenter, observational cohort study of 40 PD patients (age, 60 ± 10 years; male, 88%; median PD duration, 28 months) starting combined therapy and investigated changes in several clinical parameters, including erythropoiesis‐stimulating agent (ESA) resistance index (ERI).
Results
ERI decreased significantly during 6 months after switching to combined therapy (from 11.8 [IQR 8.0–20.4] units/week/kg/(g/dL) to 7.8 [IQR 3.9–18.6] units/week/kg/(g/dL), p = 0.047). Body weight, urinary volume, serum creatinine and the dialysate‐to‐plasma creatinine ratio (D/P Cr) decreased, whereas hemoglobin and serum albumin increased. In subgroup analysis, the changes in ERI were not affected by cause for starting combined therapy, PD holiday and D/P Cr.
Conclusion
Although detailed mechanism was unclear, ESA responsiveness improved after switching from PD alone to combined therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology and Hypertension, Department of Internal Medicine, Tokyo, Japan.
- Shibagaki Dialysis Clinic, Tokyo, Japan.
- Center of CKD and Lifestyle Related Diseases, Edogawa Hospital, Ichikawa, Japan.
- Department of Nephrology, Toho University School of Medicine, Tokyo, Japan.
- Department of Nephrology, Tokyo Medical University, Tokyo, Japan.
- Division of Nephrology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
ORCID-Profile: Yukio Maruyama, Tsutomu Sakurada
Förderung
- the Kidney Foundation, Japan
Zitieren
APA
Maruyama, Y., Yokoyama, K., Higuchi, C., Sanaka, T., Tanaka, Y., Sakai, K., Kanno, Y., Ryuzaki, M., Sakurada, T., Hosoya, T., Nakayama, M., & EARTH (Evaluation of the Adequacy of Renal replacement THerapy) study group (2023). Changes in erythropoiesis‐stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan. Therapeutic Apheresis and Dialysis, 27(4), 735-741. https://doi.org/10.1111/1744-9987.13981
Vancouver
Maruyama Y, Yokoyama K, Higuchi C, Sanaka T, Tanaka Y, Sakai K, et al. Changes in erythropoiesis‐stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan. Therapeutic Apheresis and Dialysis. 2023;27(4):735-741. doi:10.1111/1744-9987.13981
BibTeX
@article{Maruyama2023,
author = {Maruyama, Yukio and Yokoyama, Keitaro and Higuchi, Chieko and Sanaka, Tsutomu and Tanaka, Yoshihide and Sakai, Ken and Kanno, Yoshihiko and Ryuzaki, Munekazu and Sakurada, Tsutomu and Hosoya, Tatsuo and Nakayama, Masaaki and EARTH (Evaluation of the Adequacy of Renal replacement THerapy) study group, EARTH (Evaluation of the Adequacy of Renal replacement THerapy) study group},
title = {Changes in erythropoiesis‐stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan},
journal = {Therapeutic Apheresis and Dialysis},
year = {2023},
volume = {27},
number = {4},
pages = {735--741},
doi = {10.1111/1744-9987.13981}
}
EUVIMED